Update on osteoporosis from the 2014 Santa Fe Bone symposium

References

• Lewiecki EM, Baim S, Bilezikian JP, et al. 2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom 2009;12:135–57
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Bilezikian JP, Cooper C, et al. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. J Clin Densitom 2008;11:313–24
   PubMedGoogle Scholar
• Lewiecki EM. Proceedings of the Santa Fe Bone Symposium 2006. Womens Health 2006;2:825–8
   Google Scholar
• Lewiecki EM, Bilezikian JP, Laster AJ, et al. 2009 Santa Fe Bone Symposium. J Clin Densitom 2010;13:1–9
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Bilezikian JP, Khosla S, et al. Osteoporosis update from the 2010 Santa Fe Bone Symposium. J Clin Densitom 2010;14:1–21
   Web of Science ®Google Scholar
• Lewiecki EM, Bilezikian JP, Jankowski LG, et al. Proceedings of the 2011 Santa Fe Bone Symposium. J Clin Densitom 2012;15:1–20
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Adler RA, Bilezikian JP, et al. Osteoporosis Update From the 2012 Santa Fe Bone Symposium. J Clin Densitom 2013;16:584–600
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Bilezikian JP, Bonewald LF, et al. 2013 Santa Fe Bone Symposium Highlights 2013. Available from: http://2013santafebonesymposium.com [last accessed 17 Jun 2014]
   Google Scholar
• Lewiecki EM, Bilezikian JP, Miller PD, et al. Highlights from the 2009 Santa Fe Bone Symposium. Osteoporosis Foundation of New Mexico [Internet]. 2009. Available from: http://www.2009santafebonesymposium.com/downloads/2009-Santa-Fe-Bone-Newsletter.pdf [last accessed 25 Aug 2011]
   Google Scholar
• Lewiecki EM, Bilezikian JP, Khosla S, et al. Highlights from the 2010 Santa Fe Bone Symposium. Osteoporosis Foundation of New Mexico. 2010. Available from: http://santafebonesymposium.squarespace.com/storage/assets/2010_Santa_Fe_Bone.pdf [last accessed 25 Aug 2011]
   Google Scholar
• Lewiecki EM, Bilezikian JP, McCloskey EV, et al. Highlights of the 2011 Santa Fe Bone Symposium. Osteoporosis Foundation of New Mexico. 2011. Available from: http://www.2011santafebonesymposium.com/2011-Santa-Fe-Bone-Newsletter.pdf [last accessed 19 Jan 2012]
   Google Scholar
• Lewiecki EM, Bilezikian JP, Khosla S, et al. 2010 Santa Fe Bone Symposium. Osteoporosis Foundation of New Mexico. 2010. Available from: http://www.2010santafebonesymposium.com/ [last accessed 25 Aug 2011]
   Google Scholar
• Lewiecki EM, Bilezikian JP, Miller PD, et al. 2009 Santa Fe Bone Symposium. Osteoporosis Foundation of New Mexico. 2009. Available from: http://www.2009santafebonesymposium.com/ [last accessed 25 Aug 2011]
   Google Scholar
• Lewiecki EM, Bilezikian JP, Jankowski LG, et al. 2011 Santa Fe Bone Symposium Highlights. Osteoporosis Foundation of New Mexico. 2011. Available from: http://www.2011santafebonesymposium.com/presentations.html [last accessed 15 Sept 2012]
   Google Scholar
• Siris ES, Boonen S, Mitchell PJ, et al. What's in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int 2012;23:2093–7
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–95
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Shane E, de la CL, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989;4:283–91
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton LJ, III, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999;14:1700–7
   PubMed Web of Science ®Google Scholar
• Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2306–12
   PubMed Web of Science ®Google Scholar
• Hansen S, Beck Jensen JE, Rasmussen L, et al. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J Bone Miner Res 2010;25:1941–7
   PubMed Web of Science ®Google Scholar
• Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 2013;28:1029–40
   PubMed Web of Science ®Google Scholar
• Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 2014;29:518–30
   PubMed Web of Science ®Google Scholar
• Romagnoli E, Cipriani C, Nofroni I, et al. “Trabecular Bone Score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 2013;53:154–9
   PubMed Web of Science ®Google Scholar
• Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS) – a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98:1963–70
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 2014;99:3561–9
   PubMed Web of Science ®Google Scholar
• Melton LJ, III, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008;93:4804–9
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a meta-analysis. Osteoporos Int 2007;18:427–44
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495–505
   PubMed Web of Science ®Google Scholar
• Hothersall EJ, Livingstone SJ, Looker HC, et al. Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Miner Res 2014;29:1054–60
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:38
   Google Scholar
• Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012;27:301–8
   PubMed Web of Science ®Google Scholar
• Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:5045–55
   PubMed Web of Science ®Google Scholar
• Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 2013;28:313–24
   PubMed Web of Science ®Google Scholar
• Leslie WD, Aubry-Rozier B, Lamy O, et al. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013;98:602–9
   PubMed Web of Science ®Google Scholar
• Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014;29:787–95
   PubMed Web of Science ®Google Scholar
• Tanaka S, Kuroda T, Saito M, Shiraki M. Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women. J Bone Miner Res 2011;26:2778–84
   PubMed Web of Science ®Google Scholar
• Schuit SC, van der KM, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004;34:195–202
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Siu AT, Mason BH, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 2011;26:420–7
   PubMed Web of Science ®Google Scholar
• Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One 2009;4:e7038
   PubMed Web of Science ®Google Scholar
• Cawthon PM, Fullman RL, Marshall L, et al. Physical performance and risk of hip fractures in older men. J Bone Miner Res 2008;23:1037–44
   PubMed Web of Science ®Google Scholar
• Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011;12:249–56
   PubMed Web of Science ®Google Scholar
• Morley JE, Malmstrom TK. Frailty, sarcopenia, and hormones. Endocrinol Metab Clin North Am 2013;42:391–405
   PubMed Web of Science ®Google Scholar
• Binkley N, Buehring B. Beyond FRAX: it's time to consider “sarco-osteopenia”. J Clin Densitom 2009;12:413–16
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–23
   PubMed Web of Science ®Google Scholar
• Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014;69:547–58
   PubMed Web of Science ®Google Scholar
• Binkley N, Krueger D, Buehring B. What's in a name revisited: should osteoporosis and sarcopenia be considered components of “dysmobility syndrome?". Osteoporos Int 2013;24:2955–9
   PubMed Web of Science ®Google Scholar
• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–50
   Google Scholar
• Hans D, Barthe N, Boutroy S, et al. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 2011;14:302–12
   PubMed Web of Science ®Google Scholar
• Winzenrieth R, Michelet F, Hans D. Three-dimensional (3D) microarchitecture correlations with 2D projection image gray-level variations assessed by trabecular bone score using high-resolution computed tomographic acquisitions: effects of resolution and noise. J Clin Densitom 2013;16:287–96
   PubMed Web of Science ®Google Scholar
• Kolta S, Briot K, Fechtenbaum J, et al. TBS result is not affected by lumbar spine osteoarthritis. Osteoporos Int 2014;25:1759–64
   PubMed Web of Science ®Google Scholar
• Ulivieri FM, Silva BC, Sardanelli F, et al. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine 2014;47:435–48
   PubMed Web of Science ®Google Scholar
• Leslie WD, Johansson H, Kanis JA, et al. Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporos Int 2014;25:2271–7
   PubMed Web of Science ®Google Scholar
• Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 2011;26:2762–9
   PubMed Web of Science ®Google Scholar
• Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004;7:1–6
   PubMed Web of Science ®Google Scholar
• International Society for Clinical Densitometry. 2013 ISCD Official Positions – Adult 2013. Available from: http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/ [last accessed 20 Jan 2014]
   Google Scholar
• Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy X-ray absorptiometry and ultrasound in clinical practice. 2nd ed. London: Martin Dunitz; 1999
   Google Scholar
• Bonnick SL, Lewis LA. Bone densitometry for technologists. 3rd ed. New York; London: Springer; 2013. xxiii, 421 p
   Google Scholar
• Lewiecki EM, Binkley N, Petak SM. DXA quality matters. J Clin Densitom 2006;9:388–92
   PubMed Web of Science ®Google Scholar
• King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests' benefit in reducing fractures. Health Aff (Millwood) 2011;30:2362–70
   PubMed Web of Science ®Google Scholar
• Sala A, Webber C, Halton J, et al. Effect of diagnostic radioisotopes and radiographic contrast media on measurements of lumbar spine bone mineral density and body composition by dual-energy x-ray absorptiometry. J Clin Densitom 2006;9:91–6
   PubMed Web of Science ®Google Scholar
• Krueger D, Checovich M, Gemar D, et al. Calcium supplement ingestion may alter lumbar spine bone mineral density measurement. J Clin Densitom 2006;9:159–63
   PubMed Web of Science ®Google Scholar
• Densitometry ISfC. ISCD technologist study guide. Middle Town (CT): ISCD; 2012
   Google Scholar
• Ozer BH, Krueger D, Binkley N. Slight abduction/adduction deviations in femur positioning for dual-energy X-ray absorptiometry are inconsequential. J Clin Densitom 2010;13:10–17
   PubMed Web of Science ®Google Scholar
• Binkley N, Krueger D, Vallarta-Ast N. An overlying fat panniculus affects femur bone mass measurement. J Clin Densitom 2003;6:199–204
   PubMed Web of Science ®Google Scholar
• Baniak N, Grzybowski S, Olszynski WP. Dual-energy X-ray absorptiometry scan autoanalysis vs manual analysis. J Clin Densitom 2014;17:97–103
   PubMed Web of Science ®Google Scholar
• Krueger D, Vallarta-Ast N, Libber J, et al. Positioner and clothing artifact can affect one-third radius bone mineral density measurement. J Clin Densitom 2013;16:154–9
   PubMed Web of Science ®Google Scholar
• Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–95
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–9
   PubMed Web of Science ®Google Scholar
• Miller PD, Bonnick SL, Rosen CJ. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 1996;58:207–14
   PubMed Web of Science ®Google Scholar
• Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014;25:1439–43
   PubMed Web of Science ®Google Scholar
• Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 2007;18:761–70
   PubMed Web of Science ®Google Scholar
• Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 2008;26:1–8
   PubMed Web of Science ®Google Scholar
• Christiansen BA, Kopperdahl DL, Kiel DP, et al. Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis. J Bone Miner Res 2011;26:974–83
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012;97:1737–44
   PubMed Web of Science ®Google Scholar
• Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013;8:819–23
   PubMed Web of Science ®Google Scholar
• Fajardo RJ, Karim L, Calley VI, Bouxsein ML. A review of rodent models of type 2 diabetic skeletal fragility. J Bone Miner Res 2014;29:1025–40
   PubMed Web of Science ®Google Scholar
• Cohen A, Dempster DW, Recker RR, et al. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab 2013;98:2562–72
   PubMed Web of Science ®Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 2014;29:1929–37
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Laster AJ, Miller PD, Bilezikian JP. More bone density testing is needed, not less. J Bone Miner Res. 2012;27:739–42
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412–20
   PubMed Web of Science ®Google Scholar
• Recker R, Benson C, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2014
   Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–75
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004;15:175–9
   PubMedGoogle Scholar
• Rossini M, Bianchi G, Di MO, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914–21
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 2012;27:2039–46
   PubMed Web of Science ®Google Scholar
• Cohen A, Shane E. Evaluation and management of the premenopausal woman with low BMD. Curr Osteoporos Rep 2013;11:276–85
   PubMedGoogle Scholar
• Ferrari S, Bianchi ML, Eisman JA, et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2012;23:2735–48
   PubMed Web of Science ®Google Scholar
• Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994;15:551–5
   PubMed Web of Science ®Google Scholar
• Campos-Obando N, Oei L, Hoefsloot LH, et al. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause. J Clin Endocrinol Metab 2014;99:1107–11
   PubMed Web of Science ®Google Scholar
• Korvala J, Loija M, Makitie O, et al. Rare variations in WNT3A and DKK1 may predispose carriers to primary osteoporosis. Eur J Med Genet 2012;55:515–19
   PubMed Web of Science ®Google Scholar
• Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013;368:1809–16
   PubMed Web of Science ®Google Scholar
• Cohen A, Dempster DW, Recker RR, et al. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2011;96:3095–105
   PubMed Web of Science ®Google Scholar
• Cohen A, Recker RR, Lappe J, et al. Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density. Osteoporos Int 2012;23:171–82
   PubMed Web of Science ®Google Scholar
• Peris P, Monegal A, Martinez MA, et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol 2007;26:958–61
   PubMed Web of Science ®Google Scholar
• Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006;24:675–80
   PubMed Web of Science ®Google Scholar
• Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993;121:217–23
   PubMed Web of Science ®Google Scholar
• Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009;44:428–30
   PubMed Web of Science ®Google Scholar
• O'Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 2006;17:1008–12
   PubMed Web of Science ®Google Scholar
• Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004;19:1742–5
   PubMed Web of Science ®Google Scholar
• Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26:4739–45
   PubMed Web of Science ®Google Scholar
• Bussiere JL, Pyrah I, Boyce R, et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 2013;42:27–40
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011;96:972–80
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998;280:1067–73
   PubMed Web of Science ®Google Scholar
• Choe EY, Song JE, Park KH, et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab 2012;30:596–601
   PubMed Web of Science ®Google Scholar
• Cohen A, Stein EM, Recker RR, et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab 2013;98:1971–81
   PubMed Web of Science ®Google Scholar
• Cohen A, Kamanda-Kosseh M, Recker R, et al. Characteristics of premenopausal women with idiopathic osteoporosis who experience significant bone loss after teriparatide cessation. J Bone Miner Res 2014;29:S319
   Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382–7
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292–9
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277–85
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253–63
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028–39
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009;20:2095–104
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515–26
   PubMed Web of Science ®Google Scholar